Brian Skorney

Stock Analyst at Baird

(4.19)
# 692
Out of 4,486 analysts
66
Total ratings
48%
Success rate
16.35%
Average return

24 Stocks

Sarepta Therapeutics
Jun 21, 2024
Maintains: Outperform
Price Target: $170$200
Current: $152.11
Upside: +31.48%
Gilead Sciences
Jun 20, 2024
Maintains: Neutral
Price Target: $80
Current: $69.97
Upside: +14.33%
Mirum Pharmaceuticals
Jun 17, 2024
Maintains: Outperform
Price Target: $34$39
Current: $37.66
Upside: +3.56%
Lexeo Therapeutics
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $17.44
Upside: +60.55%
Crinetics Pharmaceuticals
May 23, 2024
Maintains: Outperform
Price Target: $52$62
Current: $52.81
Upside: +17.40%
Soleno Therapeutics
May 10, 2024
Initiates: Outperform
Price Target: $72
Current: $44.50
Upside: +61.80%
Marinus Pharmaceuticals
Apr 16, 2024
Downgrades: Neutral
Price Target: $20$2
Current: $1.33
Upside: +50.38%
REGENXBIO
Mar 6, 2024
Maintains: Outperform
Price Target: $34$39
Current: $12.71
Upside: +206.85%
Alto Neuroscience
Feb 27, 2024
Initiates: Outperform
Price Target: $32
Current: $13.40
Upside: +138.81%
Biogen
Feb 14, 2024
Maintains: Outperform
Price Target: $333$316
Current: $236.80
Upside: +33.45%
Biohaven Pharmaceutical Holding Company
Dec 8, 2023
Initiates: Outperform
Price Target: $58
Current: $37.95
Upside: +52.83%
Xenon Pharmaceuticals
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $41.18
Upside: +52.99%
Neurocrine Biosciences
Aug 2, 2023
Maintains: Outperform
Price Target: $140$148
Current: $146.50
Upside: +1.02%
Regeneron Pharmaceuticals
Jun 28, 2023
Maintains: Neutral
Price Target: $800$760
Current: $1,080.27
Upside: -29.65%
Vertex Pharmaceuticals
May 2, 2023
Maintains: Neutral
Price Target: $280$325
Current: $492.13
Upside: -33.96%
Applied Therapeutics
Apr 25, 2023
Maintains: Outperform
Price Target: $18$14
Current: $5.38
Upside: +160.22%
Enanta Pharmaceuticals
May 19, 2022
Maintains: Outperform
Price Target: $130$90
Current: $14.99
Upside: +500.40%
Reneo Pharmaceuticals
Jan 27, 2022
Initiates: Outperform
Price Target: $28
Current: $1.51
Upside: +1,754.30%
Immunovant
Aug 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $30.34
Upside: -
VistaGen Therapeutics
May 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.91
Upside: -
Voyager Therapeutics
Feb 26, 2021
Downgrades: Neutral
Price Target: n/a
Current: $8.94
Upside: -
Amgen
Jan 31, 2020
Downgrades: Underperform
Price Target: n/a
Current: $325.09
Upside: -
Curis
May 7, 2018
Maintains: Outperform
Price Target: n/a
Current: $6.92
Upside: -
BeiGene
Nov 14, 2017
Downgrades: Neutral
Price Target: n/a
Current: $150.50
Upside: -